Refractory Primary Amyloidosis clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
Orange, California and other locations